Veteran executive Susan Salka joins Teladoc Health (NYSE: TDOC) board
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Teladoc Health, Inc. expanded its board of directors to nine members and appointed Susan R. Salka as a new director, effective March 30, 2026. She will serve on the board’s audit and compensation committees, and has been designated an independent director and an “audit committee financial expert.” Ms. Salka is the former president and CEO of AMN Healthcare Services, where over a 33‑year tenure she helped drive 26 acquisitions and grow revenue to over $5 billion. She also brings prior board experience at several major healthcare and life sciences companies.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board size: 9 directors
AMN Healthcare revenue: over $5 billion
AMN acquisitions: 26 acquisitions
+2 more
5 metrics
Board size
9 directors
Board increased to nine members effective March 30, 2026
AMN Healthcare revenue
over $5 billion
Revenue at AMN Healthcare after 33-year tenure led in part by Salka
AMN acquisitions
26 acquisitions
Number of acquisitions completed by AMN Healthcare during Salka’s tenure
Tenure at AMN
33 years
Susan Salka’s tenure at AMN Healthcare Services
NYSE symbol
TDOC
Trading symbol for Teladoc Health common stock on NYSE
Key Terms
audit committee financial expert, independent director, Regulation FD, non-employee directors, +2 more
6 terms
audit committee financial expert financial
"and is an “audit committee financial expert” under Securities and Exchange Commission"
A person on a company’s board who has deep knowledge of accounting, financial reporting and auditing, able to understand and question the books, controls and audit work like a trained mechanic inspecting an engine. Investors care because that expertise helps spot errors, weaknesses or misleading statements early, improving the likelihood that financial reports are accurate and reducing the risk of surprises that can hurt a company’s value.
independent director financial
"The Board has determined that Ms. Salka is an independent director within the meaning"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Regulation FD regulatory
"Item 7.01 Regulation FD. On March 30, 2026, the Company issued a press release"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
non-employee directors financial
"compensation arrangements and programs that are established for the Company’s non-employee directors"
Item 404(a) of Regulation S-K regulatory
"There are no transactions involving the Company and Ms. Salka that the Company would be required to report pursuant to Item 404(a) of Regulation S-K."
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What board change did Teladoc Health (TDOC) announce on March 30, 2026?
Teladoc Health expanded its board to nine directors and appointed Susan R. Salka as a new member. She joins effective immediately and will serve on the audit and compensation committees, strengthening governance with deep healthcare and financial oversight experience.
Who is Susan Salka, the new Teladoc Health (TDOC) director?
Susan R. Salka is the former president and CEO of AMN Healthcare Services. During her 33‑year tenure there, AMN pioneered workforce solutions, completed 26 acquisitions, and grew revenue to over $5 billion, giving her extensive strategic and operational healthcare experience.
Which Teladoc Health (TDOC) board committees will Susan Salka join?
Susan Salka will serve on Teladoc Health’s audit committee and compensation committee. The board has determined she is an independent director and an “audit committee financial expert,” adding financial, governance, and healthcare industry expertise to these key oversight roles.
Is Susan Salka considered independent under NYSE rules at Teladoc Health (TDOC)?
Yes. Teladoc Health’s board determined that Susan Salka qualifies as an independent director under New York Stock Exchange listing standards. She is also designated an “audit committee financial expert” under Securities and Exchange Commission and NYSE rules, enhancing the company’s financial oversight.
How will Susan Salka be compensated as a Teladoc Health (TDOC) director?
Susan Salka will be eligible for the same compensation programs as Teladoc Health’s other non‑employee directors. These arrangements are described in the company’s Schedule 14A proxy statement filed April 8, 2025, and she will also receive the standard director indemnification agreement.